MSD has announced the
TGA approval of its biosimilar
Brenzys (etanercept) for the
treatment of rheumatoid arthritis,
spondyloarthritis, psoriatic arthritis
and psoriasis in adults aged over 18.
The next step is a potential
listing on the Pharmaceutical
Benefits Scheme, with Brenzis
set to possibly become the first
immunology biosimilar dispensed
via community pharmacy because
if the product is ‘a’-flagged by the
PBAC, pharmacists will be able to
substitute the product without
reference to the prescriber, said
MSD medical director Dr Gary
Jankelowitz.
Brenzys has also been approved
for marketing in Korea (PD 27 Jul).The above article was sent to subscribers in Pharmacy Daily's issue from 29 Jul 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Jul 16
BREAST Cancer Network Australia (BCNA) has welcomed a PBAC recommendation to subsidise the breast cancer drug Enhertu (trastuzumab deruxtecan) for HER2-low metastatic breast cancer on the PBS.
PHARMACY Connect (PC2024) has revealed that Olympian Peter Bol will be sharing his journey from adversity to athletic greatness at the conference in Sep in Sydney.
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.